| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
Industry Sector |
Healthcare and Medical |
Published |
14 November 2012 |
Author |
Mike King |
Type of News |
Market |
The global contraceptives market has been forecast to increase at a compound annual growth rate (CAGR) of 2.1% over the next six years, rising from a valuation of $10.2 billion in 2011, to hit a market value of $11.8 billion by 2018.
All sexually active women face the risk of unwanted/unplanned pregnancy right from the years spanning menarche to menopause. The unprecedented rate of population explosion has become a cause for grave concern the world over. Therefore, a keen interest in curbing the number of unintended pregnancies is one of the top priorities of governments in the developing and developed countries, alike.
Since hormonal contraception was approved in the 1960s many different treatments have been developed, but has the pill seen its glory days pass. The contraceptive market consists of short-term (oral contraceptives, patch, ring, injectables), long-term (IUD, implant) and permanent contraceptive options.
With the increasing number of women acquiring publicly-funded birth control, and a growing public awareness and acceptance, the contraceptives market is ever-growing.
The annual cost of usage within the contraceptives market was $113 in 2011, which grew from $104 in 2004, at a CAGR of 1.2%. This is expected to further increase to $125 in 2018, at a CAGR of 1.4% between 2011 and 2018. The growth rate can be attributed to factors such as the expected patent expiry of Mirena and Yaz. Through to 2018, CSD500, a condom manufactured by Futura Medical and licensed to Reckitt and Benckiser, is expected to strengthen the condom market.
The condom remains the only form of contraception to offer full protection against sexually transmitted diseases, and this doesn't look likely to change anytime soon. However, the CSD500 condom, manufactured by Futura Medical and licensed by Reckitt Benckiser, contains a pharmacologic dosage to treat erectile dysfunction, representing a development in the most stable contraceptive segment.
For more information on the global contraceptives market, see the latest research: Global Contraceptives Market
Follow us on Twitter @CandMResearch
|
All posts are pre-moderated and must obey the house rules. |
|
Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.